Daniel Paterson Net Worth

The estimated Net Worth of Dan Paterson is at least $2.51 million dollars as of 5 August 2024. Mr. Paterson owns over 3,245 units of Verastem Inc stock worth over $651,890 and over the last 12 years he sold VSTM stock worth over $122,556. In addition, he makes $1,736,170 as President et Chief Operating Officer at Verastem Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Paterson VSTM stock SEC Form 4 insiders trading

Daniel has made over 20 trades of the Verastem Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he sold 3,245 units of VSTM stock worth $7,009 on 5 August 2024.

The largest trade he's ever made was selling 23,534 units of Verastem Inc stock on 3 January 2022 worth over $48,245. On average, Daniel trades about 1,819 units every 78 days since 2013. As of 5 August 2024 he still owns at least 232,818 units of Verastem Inc stock.

You can see the complete history of Mr. Paterson stock trades at the bottom of the page.

Daniel Paterson biography

Daniel W. Paterson is President, Chief Operating Officer of the Company. Mr. Paterson has served as our President since June 2019 in addition to serving as our Chief Operating Officer since December 2014, our Chief Business Officer from July 2013 to December 2014 and as our Vice President, Head of Corporate Development and Diagnostics from March 2012 until July 2013. Prior to joining us in March 2012, Mr. Paterson was a consultant in 2011. From 2009 through 2010, Mr. Paterson was the Chief Operating Officer of On-Q-ity. Mr. Paterson was the President and Chief Executive Officer of The DNA Repair Company from 2006 until 2009, when it was acquired by On-Q-ity. Previously, he held senior level positions at IMS Health, CareTools, OnCare, and Axion. Mr. Paterson holds a B.A. in Biology from Boston University, and attended the Northeastern University Graduate Pharmacology program.

What is the salary of Daniel Paterson?

As the President et Chief Operating Officer of Verastem Inc, the total compensation of Daniel Paterson at Verastem Inc is $1,736,170. There are 1 executives at Verastem Inc getting paid more, with Brian Stuglik having the highest compensation of $1,917,190.

How old is Daniel Paterson?

Daniel Paterson is 58, he's been the President et Chief Operating Officer of Verastem Inc since 2019. There are 8 older and 7 younger executives at Verastem Inc. The oldest executive at Verastem Inc is Timothy Barberich, 72, who is the Independent Director.

What's Daniel Paterson's mailing address?

Dan's mailing address filed with the SEC is C/O VERASTEM, INC.,, 117 KENDRICK ST., SUITE 500, NEEDHAM, MA, 02494.

Insiders trading at Verastem Inc

Over the last 13 years, insiders at Verastem Inc have traded over $5,883,823 worth of Verastem Inc stock and bought 3,873,819 units worth $28,318,633 . The most active insiders traders include Capital Management, L.P.Ra ..., Christoph H Westphal et Ansbert Gadicke. On average, Verastem Inc executives and independent directors trade stock every 28 days with the average trade being worth of $112,479. The most recent stock trade was executed by Dan Paterson on 5 August 2024, trading 3,245 units of VSTM stock currently worth $7,009.

What does Verastem Inc do?

verastem, inc. (nasdaq: vstm) is a biopharmaceutical company focused on discovering and developing novel drugs that selectively target cancer stem cells. cancer stem cells are an underlying cause of tumor recurrence and metastasis. verastem is translating breakthrough discoveries in cancer stem cell research into new medicines for the treatment of major cancers such as breast cancer. for more information, please visit www.versatem.com

Complete history of Mr. Paterson stock trades at Verastem Inc

Verastem Inc executives and stock owners

Verastem Inc executives and other stock owners filed with the SEC include:

• Brian Stuglik,
  Chief Executive Officer, Director
• Daniel Paterson,
  President, Chief Operating Officer
• Robert Gagnon,
  Chief Financial Officer, Chief Business Officer
• Brian M. Stuglik BPHARM, R.Ph., RPh,
  CEO & Director
• Brian Stuglik R.Ph., RPh,
  CEO & Director
• Daniel W. Paterson,
  COO & Pres
• Robert E. Gagnon,
  Chief Bus. & Financial Officer
• Michael Kauffman,
  Lead Independent Director
• Timothy Barberich,
  Independent Director
• Eric Rowinsky,
  Independent Director
• Alison Lawton,
  Independent Director
• Bruce Wendel,
  Independent Director
• Gina Consylman,
  Independent Director
• John Doyle,
  Investor Relations
• Dr. Michelle Dipp M.D., Ph.D.,
  Co-Founder
• Sean C. Flynn,
  VP, Gen. Counsel & Sec.
• Erin S. Cox,
  Sr. Director of Investor Relations & Corp. Communications
• Dr. Jonathan Pachter Ph.D.,
  Chief Scientific Officer
• Dr. Michelle Dipp,
  Co-Founder
• Dr. Piyush B. Gupta Ph.D.,
  Co-Founder
• Dr. Robert A. Weinberg,
  nder & Former Chair of Scientific Advisory Board
• Richard H. Aldrich M.B.A., Mba,
  Founder and Consultant
• S. Louise Phanstiel,
  Director
• Joseph Chiapponi,
  Vice President of Finance
• John B Green,
  Chief Financial Officer
• Monica Singh,
  General Counsel
• Henri A Termeer,
  Director
• Stephen A Sherwin,
  Director
• Christoph H Westphal,
  Executive Chairman
• Paul A Friedman,
  Director
• Karin Anna Tollefson,
  Director
• Steven H. Bloom,
  Chief Strategy Officer
• Julie B Feder,
  Chief Financial Officer
• Robert Forrester,
  President and CEO
• Ngoc Diep T. Md, Ph D Le,
  Chief Medical Officer
• Joseph M Lobacki,
  Executive VP & CCO
• Gregory Berk,
  Chief Medical Officer
• Capital Investments L.P.Rid...,
  
• Capital Management, L.P.Ra ...,
  
• John Johnson,
  Director
• Management Co. Llc Deer,
  Director
• Iii Lp Chp,
  10% owner
• John K Clarke,
  Director
• Joanna Horobin,
  Chief Medical Officer
• Jonathan Pachter,
  VP, Head of Research
• Fund, L.P. Longwood,
  10% owner
• Venture Partners Vii L.P.Be...,
  
• Stephen Kraus,
  Director
• Ansbert Gadicke,
  Director
• Bioventures V Llcmpm Bioven...,
  
• Piyush Gupta,
  10% owner
• Iii Lpchp Iii Management, L...,
  
• Daniel Calkins,
  Chief Financial Officer
• Frank Neumann,
  Chief Medical Officer
• Paul A. Bunn,
  Director
• Lesley Kim Solomon,
  Director
• Michelle Robertson,
  Director
• Anil Kapur,
  Director
• Dan Paterson,
  President and CEO